Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Ratio (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Equity Ratio for 6 consecutive years, with 0.54 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 17.12% to 0.54 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.54, a 17.12% decrease, with the full-year FY2025 number at 0.54, down 17.12% from a year prior.
  • Equity Ratio was 0.54 for Q4 2025 at TScan Therapeutics, down from 0.55 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.87 in Q1 2022 to a low of 0.46 in Q2 2021.
  • A 5-year average of 0.59 and a median of 0.6 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: soared 287.07% in 2022, then crashed 48.11% in 2023.
  • TScan Therapeutics' Equity Ratio stood at 0.85 in 2021, then crashed by 41.57% to 0.5 in 2022, then rose by 11.0% to 0.55 in 2023, then grew by 17.13% to 0.65 in 2024, then dropped by 17.12% to 0.54 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Equity Ratio are 0.54 (Q4 2025), 0.55 (Q3 2025), and 0.59 (Q2 2025).